B. Morrigan

发表

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

A. Zelenetz, D. Brander, S. Schuster, 2018, Blood.

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION

A. Zelenetz, E. L. Luning Prak, D. Brander, 2019, Hematological Oncology.